spacer
home > epc > winter 2003 > central laboratories and the importance of an effective quality system
PUBLICATIONS
European Pharmaceutical Contractor

Central Laboratories and the Importance of an Effective Quality System

Central laboratories play a significant role in the clinical trials process by providing drug development companies with clean, combinable laboratory data, which can be analysed and reported in a timely and cost-effective manner, and which can undergo global regulatory review. Due to the critical nature of the data being generated, it is essential that data are accurate, reliable and reproducible.

So, how can a central laboratory assure its clients of the quality of the data being generated in its operation? The answer lies in the question: the laboratory must establish a quality assurance system. Establishing a quality system involves the implementation of a series of processes and procedures that standardise operations. For a quality system to be credible, it must be examined by an independent external party that is recognised as being competent in the assessment of such a system. These external parties will investigate the laboratory's compliance to a recognised quality standard or guideline and make a recommendation for registration.

There are many different quality standards and guidelines in existence that are recognised in industry. For central laboratories, some quality standards are compulsory depending on the location of operations, whilst other standards are optional and may be adopted by laboratories wishing to enhance their reputation for quality. All central laboratories based in the US are obliged to meet clinical laboratory improvement amendment (CLIA) and state requirements. Additionally, US laboratories, as well as any medical laboratory that handles patient samples which originate in the US, can choose to comply with the requirements of the College of American Pathologists (CAP). In Europe, Asia and Australasia, laboratories will typically aim to comply with the standards published by the International Organization for Standardization (ISO), or with good laboratory practice (GLP) requirements.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Clare O'Sullivan, Laboratory Manager at ICON Laboratories

Clare O'Sullivan is the Laboratory Manager at ICON Laboratories, Europe. She holds a BSc (Hons) and a Masters degree in Microbiology from the National University of Ireland, Cork. Prior to becoming Laboratory Manager, Clare worked as QA Manager for over four years in ICON Laboratories and Tibotec-Virco Ireland, now a division of Johnson and Johnson. During her career as QA Manager she gained experience in the implementation and maintenance of quality systems compliant with ISO 17025, CAP, EN45001, EN45004 and CLIA regulations in both European and US-based facilities.

spacer
Clare O'Sullivan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement